Margin Reduction using IGRT For Soft-Tissue Sarcoma: Secondary Analysis of RTOG 0630 Dian Wang, MD., Ph.D. Rush University Medical Center CTOS October.

Slides:



Advertisements
Similar presentations
Pulmonary Stereotactic Ablative Radiotherapy:
Advertisements

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
11 RTOG Sarcoma Working Group Consensus on The GTV and CTV For Preoperative Radiotherapy of Large High Grade Extremity Soft Tissue Sarcoma Dian Wang, MD.,
IMRT, Designed with Evidence-Based Bone Avoidance Objectives, Reduces the risk of Bone Fracture in the management of Extremity Soft Tissue Sarcoma Colleen.
CTOS, Boca Raton, 2005 A Radiation Treatment Planning Comparison for Lower Extremity Soft Tissue Sarcoma: Can the Future Surgical Wound Be Spared? Anthony.
In-Depth Analysis of Wound Complications Following Preoperative Radiotherapy for Lower Extremity Soft Tissue Sarcoma Patients Colleen Dickie MSc, MRT(T)(MR)
Dr.Sandeep.M Junior resident Dr.Ajaykumar Prof & HOD.
Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.
IMPACT OF TUMOR MORCELLATION ON THE NATURAL HISTORY OF UTERINE LEIOMYOSARCOMA César Serrano, Titilope Oduyebo, Judith Manola, Yang Feng, Michael G. Muto,
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement among RTOG Sarcoma Radiation and Surgical.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Treatment Guidelines for Pre-operative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel EH Baldini,
IMRT for the Treatment of Anal Cancer Kristen O’Donnell, MS3 December 12, 2007.
CTOS 2013 Radiation Oncology Session Discussion Elizabeth H Baldini, MD, MPH Associate Professor of Radiation Oncology Harvard Medical School Brigham and.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
H Ariyaratne1,2, H Chesham2, J Pettingell2, K Sikora2, R Alonzi1,2
Howard M. Sandler, MD University of Michigan Medical School
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.
CTOS Soft Tissue Sarcoma of the Extremity Comparison of Conformal Post-operative Radiotherapy (CRT) and Intensity Modulated Radiotherapy (IMRT)
RTOG1106: Randomized Phase IIR Trial of Personalized Adaptive Radiotherapy Based on Mid-treatment FDG-PET in Locally Advanced NSCLC P.I.: Feng-Ming (Spring)
Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.
Adductor Compartment STS - Does method of treatment affect outcome? Anup Pradhan, Yiu-Chung Cheung Birmingham Medical School, UK Supervisors: Mr Robert.
HCI Sarcoma Services Sequential Dependency of Radiotherapy for Soft-Tissue Sarcoma S Sampath TE Schultheiss YJ Hitchcock RL Randall DC Shrieve JYC Wong.
Quantifying the Morbidity of the Unplanned Sarcoma Excision
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
Irradiation of stem cell niches in the periventricular and sub granular zones in gbm : A Prospective study Akram K S, Monica I, Deepa J, Kesava R, Fayaz.
12 th Annual CTOS Meeting 2006 No of chordomas in NIRS Back ground: The number of chordomas treated with carbon ion radiotherapy have increased annually.
NSABP C08 adjuvant colon cancer Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.
Adequate 3D Treatment Volume in Preoperative Radiotherapy in Extremity Soft Tissue Sarcoma Kim BK, Chen YL, Kirsch DG, Kobayashi W, Goldberg S, Wolfgang.
Five year results of a randomized Phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma Brian O'Sullivan, Aileen.
Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,
Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.
CTOS, Berlin 2014 The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications.
Radiation Therapy Connective Tissue Oncology Society 2005 Thomas F. DeLaney, M.D.
The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
ACOSOG Sarcoma Committee Chair: Peter W.T. Pisters, MD Vice Chairs: Edward Cheng, MD (Orthopedic Oncology) Robert Maki, MD, PhD (Medical Oncology) Brian.
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Cancer Hospital & Institute, Chinese Academy of Medical Sciences
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
A U.S. GI INTERGROUP TRIAL
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.
盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Adjuvant Radiation is Required for Gastric Cancer
Neoadjuvant Adjuvant Curative Palliative
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Presentation transcript:

Margin Reduction using IGRT For Soft-Tissue Sarcoma: Secondary Analysis of RTOG 0630 Dian Wang, MD., Ph.D. Rush University Medical Center CTOS October 17, 2014

Contributing Authors Allen Li, Ph.D., Medical College of Wisconsin, USA Xiaojian Chen, PhD Medical College of Wisconsin, USA Qiang Zhang, Ph.D. NRG Oncology Statistics, USA David G. Kirsch, MDDuke University Medical Center, USA Ivy Petersen, MDMayo Clinic, USA Thomas F. DeLaney, MD Massachusetts General Hospital, USA Carolyn R. Freeman, MD McGill University Health Centre, CA Andy Trotti, MD. H. Lee Moffitt Cancer Ct Res Inst, USA Ying Hitchcock, MD University of Utah, USA Meena Bedi, MD Medical College of Wisconsin, USA Michael Haddock, MD Mayo Clinic, USA Anurag Singh, MD Roswell Park Cancer Institute, USA George Dundas, MD Cross Cancer Institute, CA Dian Wang, MD Rush University Medical Center, USA

Disclosure None

IGRT, especially IG-IMRT, decreases late side effects of the patients with soft tissue sarcoma of the extremity –A multicenter phase II trial of preoperative image- guided radiotherapy for soft tissue sarcoma of the extremity (RTOG 0630) (Wang et al., ASTRO 2013) –A single institutional phase II trial of preoperative image-guided IMRT for soft tissue sarcoma of the lower extremity (O’Sullivan et al., Cancer 2013) –A retrospective review of a single institutional experience (Alektiar et al., JCO 2008) However, what is the impact of different pretreatment imaging modalities? Background

IMRT decreases RT side effects No of pts Med F/U (mo) RTLCFibrosisEdemaJoint stiffness Davis Radiol 2005 Phase III (multi-) Preop vs. postop 2D >90%31.5% vs. 48.2% postop 15.1% vs. 23.2% postop 17.8% vs. 23.2% postop Alektiar JCO 2008 Retro- (single) 4135Postop IMRT 94%?12.2%17.2% O’Sullivan Cancer 2013 Phase II (single) 7049Preop IMRT 93%9.3%11.1%5.4% Wang ASTRO 2013 Phase II (multi- RTOG 0630) 8643Preop IMRT 75% 3DCRT 25% 93%5.3%3.5%5.3%

Primary objective: –Determine the effect of a reduced RT volume using IGRT on late radiation morbidity at 2 years from the start of RT Late morbidity defined as Grade 2 or higher: (1) edema scored by Stern’s scale (2) subcutaneous fibrosis scored by RTOG/EORTC criteria (3) joint stiffness scored by RTOG/EORTC criteria Secondary objectives: –Determine the pattern of failure RTOG 0630 A phase II trial of preoperative image-guided radiotherapy for soft tissue sarcoma of the extremity

RTOG 0630 Schema ↓ Cohort A pre-operative IGRT + chemotherapy 50 Gy delivered in 25 fractions - 3DCRT or IMRT - IGRT: 3D or 2D imaging Chemotherapy: Neoadjuvant Concurrent or interdigitated Adjuvant Closed due to poor accrual (12 patients) Cohort B pre-operative IGRT only 50 Gy delivered in 25 fractions - 3DCRT or IMRT - IGRT: 3D or 2D imaging Surgery 4-8 weeks later For a positive margin EBRT: 16 Gy in 8 fx Brachytherapy: LDR (16 Gy) or HDR (3.4 Gy X 4 fx) IORT: Gy in 1 fx ↓ ↓ Completed 03/ /2010): 86 patients

IGRT: Daily Pre-treatment Images Daily pretreatment images were required: –Bony structure adjacent to the gross tumor PTV: standard for position adjustment –An error of > 5 mm after shifts based on the pretreatment images is unacceptable The following six pre-treatment images were collected from RTOG 0630 –3D images KV fan-beam CT (KVCT) MV fan-beam CT (MVCT) KV cone-beam (KVCB) MV cone-beam (MVCB) –2D orthogonal images KV Orthogonal images (KVorth) MV Orthogonal images (MVorth)

Clinical outcomes of Cohort B Significant reduction of late radiation morbidities (grade 2+ subcutaneous fibrosis, joint stiffness and edema) when compared to NCIC SR2 Trial Preoperative RT Arm 10.5% RTOG 0630 vs. 37% NCIC SR2 (p=0.0005) Resection of blood vessels has borderline significance on late effects Rate of local failure after surgery (6.8% at 2.8 years) is within expected range and are all in-field failures Absence of marginal recurrences and the favorable late effect profile at 2 years indicates that the parameters of radiotherapy in RTOG 0630 can be utilized for pre- operative IGRT of extremity STS

Secondary Analysis: Objectives Six IGRT modalities were used in the RTOG 0630 trial. We analyzed all the daily patient-repositioning data collected in this trial to (1) compare the performance of the six IGRT modalities, (2) determine the impact of daily image guidance, and (3) estimate required CTV-to-PTV margins

Secondary Analysis: Data Collection Prospective Data Collection from participating institutions # of institutions: 18 # of patients: 98 All patients were repositioned daily based on bony anatomy registration using the pretreatment imaging, including KVCT, KVCB, MVCT, MVCB, KVorth and MVorth

Secondary Analysis: Methodology Daily patient repositioning data, including shifts in right-left (RL), superior-inferior (SI) and anterior-posterior (AP) directions and rotations in pitch, roll and yaw were analyzed The mean and standard deviations (SD) for each shift and rotation were calculated for each patient and for each IGRT modality. For the two most commonly used modalities MVCT (25/98) and KVorth (44/98), the t-test and F-test were performed to analyze the differences in their means and SDs The CTV-to-PTV margins were estimated using 2.5∑+0.7σ, where ∑ and σ were systematic and random positioning errors, respectively, based on the data for MVCT and KVorth

Secondary Analysis: Results Between MVCT and KVorth, there were no statistically significant differences in the shifts and rotations (p>0.1), except in the shifts in AP direction (2.2 vs mm, p<0.002) Daily Repositioning Shifts (mean ± SD) mm) : Modality Right-Left (RL)Superior-Inferior (SI)Anterior-Posterior (AP) KVCT 0.5±4.21.7± ±4.3 KVCB 0.35± ±1.82.5±5.6 MVCT 1.0± ±3.12.2±3.3 MVCB 1.1±8.01.2± ±4.4 KVorth -0.5±4.00.0± ±3.2 MVorth 1.0±2.73.7±6.50.1±4.0 For the two most commonly used modalities (MVCT and KVorth) the mean±SD of pitch rotations were -0.1±1.0 and 0.4±1.3 deg, respectively

Secondary Analysis: Results Average shifts in x, y, and z directions for each patients for six modalities

Secondary Analysis: Results Modality Systematic Error (  )Random Error (  ) Margin x (mm) y (mm) z (mm) x (mm) y (mm) z (mm) x (mm) y (mm) z (mm) KVCT KVCB MVCT MVCB KVorth MVorth The estimated CTV-to-PTV margins in RL, SI and AP directions required in the absence of daily IGRT would be 13.0, 10.4, and 11.7 mm from MVCT data, and 13.1, 8.6, and 10.8 mm from KVorth data, respectively

Secondary Analysis: Conclusions  Differences between six available IGRT modalities for positioning patients with soft-tissue sarcoma of the extremity based on bony anatomy were not significant except for  Shifts in AP were significantly different between MVCT and KVorth (2.2 vs. -0.5, p<0.002)  The observed large daily repositioning errors as well as large variations between institutions (data not shown) imply that daily IGRT is necessary for this tumor site, particularly in a multi-institutional trial  Otherwise, a CTV-to-PTV margin of 1.5 cm is required to account for daily variations

Acknowlegement NRG/RTOG HQ All investigators and patients from participating institutions This project was supported by RTOG grant U10 CA21661, CCOP grant U10 CA37422, and ATC grant U24 CA81647 from the National Cancer Institute (NCI)

Patient Characteristics Location –Thigh 58.3% – Leg 20.3% Median Size 10.5 cm ( cm) Histology –UPS 21.5% –Myxofibrosarcoma 20.3% –Myxoid Liposarcoma 12.7% –LMS 10.2% Grade: G3 46.8%, G2 24.1%

Treatment Delivered for 79 patients Radiation Type –3DCRT - 20 (25.3%) –IMRT - 59 (74.7%) Surgery – 74 (93.7%) R (73%) R (24.3%) R % –5 patients did not undergo surgery because of metastatic disease Radiiotherapy ReviewPercent Per Protocol55.7% Acceptable Variation32.9% Unacceptable Variation10.1%

Outcomes for 79 patients Major Wound Complications: overall 36.6% (42% for LE) –Exclusively in lower extremity Median Follow-up: 2.82 years ( years) Local Failure –5 patients without surgery –5 patients out of 74 with recurrence after surgery (6.8%) Metastasis and Survival Percent Distant Metastasis40.5% Death29.1%